What is the recommended initial management and first‑line pharmacologic treatment for essential hypertension in an otherwise healthy adult?

Initial Management and First-Line Treatment of Essential Hypertension

For an otherwise healthy adult with essential hypertension, begin with a thiazide-like diuretic (chlorthalidone 12.5–25 mg once daily) as the single best first-line agent, based on the strongest mortality and morbidity reduction evidence from the ALLHAT trial. 1, 2

Confirm the Diagnosis Before Treatment

• Verify elevated office readings (≥130/80 mmHg) with out-of-office measurements: home blood pressure monitoring averaging ≥135/85 mmHg or 24-hour ambulatory monitoring ≥130/80 mmHg. 1
• Obtain at least two readings on each of three separate clinic visits using proper technique: patient seated with back supported, feet flat, arm at heart level, after 5 minutes of rest. 1
• Measure baseline serum creatinine/eGFR, electrolytes, fasting glucose/HbA1c, lipid panel, and urinalysis for proteinuria before starting medication. 1

Initiate Lifestyle Modifications Simultaneously

All patients with blood pressure >120/80 mmHg require lifestyle changes alongside pharmacotherapy:

• DASH diet: 8–10 servings of fruits/vegetables daily, 2–3 servings of low-fat dairy, whole grains, reduced saturated fat (lowers BP by ~11/5 mmHg). 1
• Sodium restriction: <2,000 mg/day (reduces systolic BP by 5–10 mmHg). 1, 3
• Weight loss: Target BMI 20–25 kg/m²; each 10-kg reduction lowers BP by ~6/5 mmHg. 1, 3
• Physical activity: ≥150 minutes/week of moderate-intensity aerobic exercise (reduces BP by ~4/3 mmHg). 1
• Alcohol moderation: ≤2 drinks/day for men, ≤1 drink/day for women. 1
• Smoking cessation: Mandatory for all patients. 1

Pharmacologic Treatment Strategy by Blood Pressure Stage

Stage 1 Hypertension (130–139/80–89 mmHg)

• Low cardiovascular risk (<10% 10-year ASCVD risk): Start lifestyle modifications alone; reassess in 3–6 months and add medication only if BP remains elevated. 1
• High cardiovascular risk (≥10% 10-year ASCVD risk, diabetes, CKD, or established CVD): Initiate single-agent pharmacotherapy immediately alongside lifestyle changes; reassess in 1 month. 1, 2

Stage 2 Hypertension (≥140/90 mmHg)

• Start dual-agent combination therapy from two different classes at the initial visit, preferably as a single-pill combination. This achieves faster control and improves adherence compared to sequential monotherapy. 1, 2
• Reassess blood pressure in 1 month after initiation. 1

Very High Blood Pressure (≥180/110 mmHg)

• Provide immediate evaluation and start two antihypertensive agents at full doses. 1

First-Line Medication Selection

For Non-Black Patients Without Comorbidities

Chlorthalidone 12.5–25 mg once daily is the optimal first choice based on the ALLHAT trial showing superior outcomes for mortality, stroke, and heart failure compared to ACE inhibitors and calcium channel blockers. 2, 4, 5

Alternative first-line options (if chlorthalidone is not tolerated):

• Amlodipine 5–10 mg once daily (equally effective for all cardiovascular events except heart failure). 2
• Lisinopril 10–40 mg once daily (effective, particularly if albuminuria or coronary disease). 1, 2
• Losartan 50–100 mg once daily (equivalent efficacy to ACE inhibitors). 2

For Black Patients Without Comorbidities

• Start with a calcium channel blocker (amlodipine 5–10 mg) plus a thiazide-like diuretic (chlorthalidone 12.5–25 mg) as initial dual therapy. 1, 2
• Avoid ACE inhibitors or ARBs as monotherapy in this population due to reduced response. 1, 2

For Patients With Specific Comorbidities

• Chronic kidney disease or albuminuria (≥30 mg/g): ACE inhibitor or ARB is mandatory as first-line therapy to slow renal disease progression. 1, 2
• Coronary artery disease: ACE inhibitor or ARB preferred; add beta-blocker if prior myocardial infarction or angina. 1, 2
• Diabetes mellitus: ACE inhibitor or ARB preferred, especially if albuminuria present. 2
• Heart failure with reduced ejection fraction: Beta-blocker (carvedilol, metoprolol succinate, or bisoprolol) plus ACE inhibitor/ARB plus mineralocorticoid receptor antagonist. 1

Blood Pressure Targets

• Primary target for adults <65 years: <130/80 mmHg. 1, 2
• For adults ≥65 years: Systolic <130 mmHg if tolerated. 1, 2
• Minimum acceptable target for all patients: <140/90 mmHg. 1, 6
• High-risk groups (diabetes, CKD, established CVD): <130/80 mmHg. 1, 2

Titration and Escalation Algorithm

Goal: Achieve target BP within 3 months. 1

1. If BP not at goal on single agent after 4 weeks: Add a second agent from a different class (e.g., ACE inhibitor + calcium channel blocker, or ACE inhibitor + thiazide). 1
2. If still uncontrolled on two agents: Add a third agent to form the standard triple regimen (ACE inhibitor/ARB + calcium channel blocker + thiazide diuretic). 1
3. For resistant hypertension (uncontrolled on three drugs including a diuretic): First verify medication adherence, then switch to chlorthalidone if not already used and add spironolactone 25–50 mg daily (provides additional reduction of ~20/10 mmHg). 1

Monitoring After Medication Initiation

• Re-measure office BP 2–4 weeks after any medication change. 1
• Check serum creatinine/eGFR and electrolytes 7–14 days after starting an ACE inhibitor, ARB, or diuretic to detect hyperkalemia or acute kidney injury. 1, 2
• Follow up every 1–3 months until BP is controlled, then every 3–6 months. 2
• Monitor for hypokalemia when using thiazide diuretics. 1

Critical Pitfalls to Avoid

• Do not delay pharmacotherapy for a trial of lifestyle modification alone in patients with BP ≥140/90 mmHg; start medications concurrently with lifestyle changes. 1
• Do not use monotherapy for stage 2 hypertension (≥140/90 mmHg); dual therapy is required for rapid control. 1
• Avoid combining an ACE inhibitor with an ARB due to increased risk of hyperkalemia and kidney injury without added cardiovascular benefit. 1, 2
• Reserve beta-blockers for compelling indications (post-MI, heart failure, angina, atrial fibrillation); they are less effective than other first-line classes for stroke prevention in uncomplicated hypertension. 1
• Prefer chlorthalidone over hydrochlorothiazide when available for superior 24-hour BP control and cardiovascular outcomes (chlorthalidone has a 24–72 hour duration vs. 6–12 hours for hydrochlorothiazide). 1, 2
• Confirm medication adherence before labeling treatment as failure; non-adherence is the most common cause of apparent treatment resistance. 1, 3
• Do not delay treatment intensification when BP remains ≥140/90 mmHg after 4 weeks; prompt escalation within 2–4 weeks is required to reduce cardiovascular risk. 1
• Avoid ACE inhibitors, ARBs, mineralocorticoid receptor antagonists, and direct renin inhibitors in women who are pregnant or planning pregnancy due to risk of fetal injury and death. 1